EN DE
Watch Guangzhou Baiyunshan Pharma for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Guangzhou Baiyunshan Pharma (0874) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Guangzhou Baiyunshan Pharma stock HK$33.25, price HK$12.58, upside +164.3%, quality 53 out of 100. Rating: strongly undervalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Home China · ISIN CNE100000387

GB Guangzhou Baiyunshan Pharma logo Some data Nov 11, 2026

Guangzhou Baiyunshan Pharma

0874 · HK

Cheap (62% below fair value) and solid company, but falling price: meets 2 of 3 rules.

Get notified free when this changes
Fair value HK$33.25 · Strongly undervalued 
Low debt 
Ranks above peers (10/14) 
Even on cautious assumptions the value is 107% above the price (HK$26.08). 
Quality 53/100 
Expensive Growth (revenue 5y +4.7 %/yr in CNY) 
Thin margins · 2.8% net margin (TTM) 
6.9% dividend yield · Watch coverage
Some data 
Falling price (downtrend) 
Negative free cash flow 
Narrow moat 32/100
Watch Guangzhou Baiyunshan Pharma for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$21.89 HK$12.58 Fair Value HK$33.25 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range HK$12.58 – HK$21.89 · fair‑value band HK$26.08 – HK$53.76 · the HK$12.58 price screens below the HK$33.25 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow Guangzhou Baiyunshan Pharma in your weekly email

Every Wednesday you see whether Guangzhou Baiyunshan Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the pharmaceutical and healthcare industry in the People's Republic of China and internationally.

Show moreShow less

The company operates through Modern Chinese Medicine Business, Chemical Pharmaceutical Technology Business, Natural Beverage Business, Pharmaceutical Commercial Business, and Other segments.

It is involved in the research, development, manufacturing, and sale of chemical drugs, chemical raw materials, and chemical raw material intermediates; and research, development, production, and sale of health products; and wholesale, retail, and import export of Western medicines, traditional Chinese medicines, and medical devices.

The company also offers bio-innovation, consumer health, and medical services; Xiaochaihu granules; Qingkailing and Baoji, Xia Sangju product series; Angong Niuhuang, Zishen Yutai, Xiaoke, Huatuo Zaizao, Zhuangyao Jianshen, and Shujin Jianyao pills; compound Danshen and Naoxinqing tablet series; Banlangen, Compound Banlangen, and Dashen Kouyanqing granules series; and honey-processed Chuanbei and Shedan Chuanbei loquat syrup.

In addition, it provides antibacterial and anti-inflammatory drugs, andrological drugs, and analgesics and antipyretics; Wanglaoji herbal tea, Ciningji series, Lixiaoji series, and Yerou coconut milk; and advertising services.

Further, the company engages in the medical research industry; technology services industry; leasing and business services; and scientific research and technical services industry. It operates through hospitals, community healthcare facilities, and retail outlets through distributors and agents.

The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.

Stock analysis

Guangzhou Baiyunshan Pharma (0874) currently trades at HK$12.58, while our model-based Fair Value estimate is HK$33.25, implying the stock looks roughly 62% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of HK$52.50 per share, and 16 of the 17 models we run sit above the HK$12.58 price.

Bear case: the Asset-Based group reads lowest at HK$12.27, and 1 of the 17 models stay below the price. Data coverage for this calculation is medium.

Scenario range: HK$26.08 (bear) to HK$53.76 (bull), the price of HK$12.58 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Guangzhou Baiyunshan Pharma reported revenue of 77.7B CNY in FY2025 versus 69.0B CNY in FY2021, a compound +3.0%/yr. Reported net income was 3.0B CNY in FY2025, compounding −5.4%/yr from FY2021.

Key figures

Market cap HK$21.4B (≈ $2.7B) Mid · P/E ratio 8.7 · P/S ratio 0.23 · EPS (TTM) HK$1.24 · Dividend yield 6.9% · Net margin 2.8% · Return on equity 5.5% · Return on assets (EBIT) 5.8% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 34% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 164%, 0874 screens cheaper than that median.

Fair Value models

Bear HK$26.08 Fair Value HK$33.25 Bull HK$53.76
Price HK$12.58 · Upside +164.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (HK$0.3271 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income HK$26.09 HK$27.95 HK$31.28 76
Owner Earnings HK$22.02 HK$33.26 HK$53.78 75
EPV HK$33.44 HK$37.39 HK$40.85 74
All 17 models by family
DCF Models
Owner Earnings HK$22.02 HK$33.26 HK$53.78 75
Earnings-Based
Graham-Dodd HK$16.81 HK$87.64 HK$121.24 63
Lynch FV HK$28.48 HK$40.69 HK$52.90 61
PEG = 1.0 HK$28.48 HK$40.69 HK$52.90 57
EPV HK$33.44 HK$37.39 HK$40.85 74
Dividend Discount
Gordon GGM HK$9.64 HK$20.06 HK$31.84 66
DDM Multi-Stage HK$9.64 HK$16.91 HK$21.05 66
Multiples
P/E Multiple HK$40.79 HK$54.38 HK$67.98 63
P/S Multiple HK$31.52 HK$42.02 HK$52.53 58
P/B Multiple HK$24.29 HK$32.39 HK$40.49 55
EV/EBIT HK$33.57 HK$46.35 HK$59.13 66
EV/EBITDA HK$34.91 HK$48.13 HK$61.36 67
EV/Revenue HK$22.60 HK$34.33 HK$46.05 53
Asset-Based
NCAV (Graham) HK$8.10 HK$12.27 HK$15.33 55
Economic Profit
Residual Income HK$26.09 HK$27.95 HK$31.28 76
ROIC Compounder HK$34.69 HK$44.51 HK$54.56 72
Growth Earnings
Growth-Adj P/E HK$36.75 HK$52.50 HK$68.25 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 53/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 38
How much profit the company makes from its sales and capital
Quality Growth 42
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 63
Debt, balance sheet and risk of trouble
Investment 84
Does it invest with discipline instead of growing at any price?
Low Volatility 96
How calm the share price moves, does not count
Price momentum 17
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+3.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.7%
Start year 2020 (pandemic). Over 10 years: +15.0% a year
Revenue growth 28 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.2%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+5.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−1.3%
Dividend (yield on the price)6.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−1.3% vs 6.2%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 5%
Pace: the 5-year rate starts in 2020 (pandemic)

Watch 0874, get fair value alerts →

Compare Guangzhou Baiyunshan Pharma with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 81 stocks

Beats the industry median on 10/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 53 · Above median
Fair Value upside +164.3% · Top 25%
Profitability
Return on equity (12 months) 5.5% · Below median
Return on assets 3.5% · Above median
Net margin (12 months) 2.8% · Above median
Operating margin (12 months) 2.8% · Below median
Growth and dividend
Revenue growth (quarter YoY) 1.1% · Below median
Dividend yield (12 months) 6.9% · Top 25%
Balance sheet
Debt / equity 0.08× · Above median

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/E (12 months) 8.7× · Cheapest 25%
P/B 0.48× · Cheapest 25%
P/S (12 months) 0.23× · Cheaper than median
EV/EBITDA 2.2× · Cheapest 25%
PEG 0.61× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 37
FUTURE (revenue growth)6 · sector 18
PAST (return on equity)22 · sector 25
HEALTH (low debt)96 · sector 96
DIVIDEND (yield)100 · sector 54

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Sinopharm Group 1099 HK$16.67 HK$50.01 +200% vs 0874
Jointown Pharmaceutical Group 600998 ¥5.09 ¥11.56 +127% vs 0874
Shanghai Pharmaceuticals Holding 601607 ¥16.13 ¥35.78 +122% vs 0874
China National Medicines Corporation 600511 ¥28.38 ¥58.47 +106% vs 0874
Cencora, Inc COR $359.03 $341.58 −5% vs 0874
Henry Schein, Inc HSIC $86.22 $78.69 −9% vs 0874
McKesson Corporation MCK $1,103 $822.74 −25% vs 0874
Galenica AG GALE CHF 91.20 CHF 61.79 −32% vs 0874
Cardinal Health, Inc CAH $281.10 $163.14 −42% vs 0874
Asker Healthcare Group ASKER kr 74.45 kr 28.26 −62% vs 0874

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Guangzhou Baiyunshan Pharma: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Guangzhou Baiyunshan Pharma Fair Value". https://www.fairvalue-calculator.com/stock/0874

Frequently asked questions

Is Guangzhou Baiyunshan Pharma (0874) overvalued or undervalued?
As of Nov 11, 2026, our model estimates a fair value of HK$33.25 versus a price of HK$12.58, about +164% upside (undervalued).
What is the fair value of 0874?
Our model-based fair value for Guangzhou Baiyunshan Pharma is HK$33.25 (as of Nov 11, 2026), built from audited fundamentals. The current price: HK$12.58.
What is the quality score of 0874?
Guangzhou Baiyunshan Pharma has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Guangzhou Baiyunshan Pharma (0874)?
Our model-based price target is the fair value of HK$33.25 (as of Nov 11, 2026) from 17 valuation models. Cautious scenario HK$26.08, optimistic scenario HK$53.76. It is a calculation from audited fundamentals, not an analyst target.
What is the Guangzhou Baiyunshan Pharma stock forecast for 2026?
Our models put fair value at HK$33.25, about +164% upside versus a price of HK$12.58 (undervalued). Cautious scenario HK$26.08, optimistic scenario HK$53.76. The calculation is refreshed regularly with new filings.
What is the revenue of Guangzhou Baiyunshan Pharma (0874)?
Guangzhou Baiyunshan Pharma reported trailing-twelve-month revenue of about 78.1B CNY (latest available figure, as of Nov 11, 2026).
Does Guangzhou Baiyunshan Pharma pay a dividend?
Guangzhou Baiyunshan Pharma currently shows a dividend yield of 6.86% relative to its recent price (as of Nov 11, 2026).
How much is the dividend of Guangzhou Baiyunshan Pharma (0874) and when is the ex-dividend date?
Guangzhou Baiyunshan Pharma pays a dividend of HK$0.863 per share a year, a dividend yield of 6.9%. The last ex-dividend date was Sep 3, 2026. A dividend has been paid every year since 2014. The payout ratio is 42.5% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Guangzhou Baiyunshan Pharma (0874)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Guangzhou Baiyunshan Pharma it is HK$33.25 per share (as of Nov 11, 2026), against a price of HK$12.58. It is the blended result of 17 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Guangzhou Baiyunshan Pharma stock overvalued or undervalued in 2026?
As of Nov 11, 2026, 0874 trades below its calculated fair value: price HK$12.58, fair value HK$33.25, a gap of about +164% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0874?
No. The price is what the market pays today (HK$12.58); the fair value is what the company's own numbers justify (HK$33.25). For Guangzhou Baiyunshan Pharma the two are HK$20.67 per share apart. That gap is exactly why we show both numbers side by side.
How much is Guangzhou Baiyunshan Pharma worth?
The market values Guangzhou Baiyunshan Pharma at about HK$21.4B (market capitalisation, as of Nov 11, 2026). Per share that is HK$12.58; our models calculate a fair value of HK$33.25 per share.
What do the bullish and bearish scenarios say about 0874?
Our models span a range for Guangzhou Baiyunshan Pharma: cautious scenario HK$26.08, base HK$33.25, optimistic HK$53.76 per share (as of Nov 11, 2026, price HK$12.58). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0874?
Guangzhou Baiyunshan Pharma trades at a price-to-earnings ratio of 8.7 (as of Nov 11, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$33.25 is built from several models across several years. Other multiples: PEG 0.6, P/B 0.5, P/S 0.2, EV/EBITDA 2.2.
What is the PEG ratio of 0874?
The PEG ratio of Guangzhou Baiyunshan Pharma is 0.61 (P/E divided by earnings growth, as of Nov 11, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Guangzhou Baiyunshan Pharma (0874)?
Balance-sheet figures for Guangzhou Baiyunshan Pharma (as of Nov 11, 2026): return on equity 5.5%, debt of 0.08 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is 0874 from its 52-week high?
Guangzhou Baiyunshan Pharma trades at HK$12.58, about 34% below its 52-week high of HK$19.09 and at the low of HK$12.58 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$33.25 is for.
Which stocks are comparable to Guangzhou Baiyunshan Pharma?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Guangzhou Baiyunshan Pharma stock attractive at the current price?
The data as of Nov 11, 2026: price HK$12.58, calculated fair value HK$33.25 (+164%), Quality Score 53/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0874 calculated?
We run Guangzhou Baiyunshan Pharma through 17 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$33.25 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1% above its aggregate fair value. Guangzhou Baiyunshan Pharma currently trades 62% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Guangzhou Baiyunshan Pharma (0874)?
The closing price on Nov 13, 2026 was HK$12.58. Our model-based fair value is HK$33.25, about +164% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Guangzhou Baiyunshan Pharma right now?
The price is below even our cautious bear case (HK$26.08). The market is more pessimistic than our downside scenario. Solid quality (53/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (HK$26.08 to HK$53.76) leaves room in how you read the outcome.
Where does the earnings growth of Guangzhou Baiyunshan Pharma (0874) come from?
Earnings per share at Guangzhou Baiyunshan Pharma grew 8.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +13.9 %, EBIT margin −3.3 %, tax rate +0.2 %, residual (interest, one-offs) −2.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Guangzhou Baiyunshan Pharma

How large is the market capitalisation of Guangzhou Baiyunshan Pharma (0874)?
The market capitalisation of Guangzhou Baiyunshan Pharma is HK$21.4B (≈ $2.7B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Guangzhou Baiyunshan Pharma (0874)?
The price-to-sales ratio of Guangzhou Baiyunshan Pharma is 0.23 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Guangzhou Baiyunshan Pharma (0874)?
Earnings per share at Guangzhou Baiyunshan Pharma are HK$1.24 (price ÷ EPS = P/E 8.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Guangzhou Baiyunshan Pharma (0874)?
The dividend yield of Guangzhou Baiyunshan Pharma is 6.9% (payout 69.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Guangzhou Baiyunshan Pharma (0874)?
The net margin of Guangzhou Baiyunshan Pharma is 2.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Guangzhou Baiyunshan Pharma (0874)?
The return on equity (ROE) of Guangzhou Baiyunshan Pharma is 5.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Guangzhou Baiyunshan Pharma (0874)?
On an EBIT basis the return on assets of Guangzhou Baiyunshan Pharma is 5.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Guangzhou Baiyunshan Pharma (0874)?
The operating margin of Guangzhou Baiyunshan Pharma is 2.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Guangzhou Baiyunshan Pharma (0874)?
Revenue at Guangzhou Baiyunshan Pharma is growing 1.1% versus a year earlier (3y avg +3.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Guangzhou Baiyunshan Pharma (0874)?
Earnings per share at Guangzhou Baiyunshan Pharma are down 50.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Guangzhou Baiyunshan Pharma (0874) generate?
The free cash flow of Guangzhou Baiyunshan Pharma is −954M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Guangzhou Baiyunshan Pharma (0874) carry?
The net debt of Guangzhou Baiyunshan Pharma is 5.8B CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Guangzhou Baiyunshan Pharma in the live analysis

One click puts Guangzhou Baiyunshan Pharma on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.